
No results matched your search
B.Riley Financial analyst Mayank Mamtani maintained a Buy rating on Madrigal Pharmaceuticals (NASDAQ:MDGL) Inc on Friday, setting a price target of $174, which is approximately 50.62% above the present share price of $115.52.
Mamtani expects Madrigal Pharmaceuticals Inc to post earnings per share (EPS) of -$3.75 for the first quarter of 2021.
The current consensus among 12 TipRanks analysts is for a Moderate Buy rating of shares in Madrigal Pharmaceuticals, with an average price target of $168.27.
The analysts price targets range from a high of $204 to a low of $123.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $0 and a net profit of -$58.79 million. The company's market cap is $1.78 billion.
According to TipRanks.com, B.Riley Financial analyst Mayank Mamtani is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 33.9% and a 57.64% success rate.
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.